Amarin Corp Plc (AMRN)

[Mogwai]

BP pays up and takes on risk. They require neither regulatory/trial certainty or a low price. Cases in point:

http://www.fiercebiotech.com/r-d/updated-deadly-tox-threat-kills-bristol-myers-2-5b-hep-c-prospect

http://www.bloomberg.com/news/articles/2011-11-21/gilead-to-acquire-pharmasset-for-11-billion-to-add-hepatitis-c-medicines

http://www.reuters.com/article/us-healthcare-mergers-idUSTRE8092GG20120110

This is a myth thrown out there by AMRN apologists to explain away why no BP has made a push to acquire AMRN (a so called $8m company) when the market cap is sub-$300m. The idea that no BP would be interested and would require REDUCE-IT results is absurd. The competitive landscape in BP is fierce and BPs will pay up. The lack of any bids (or even rumors of interest) is extremely disturbing.